<?xml version="1.0" encoding="utf-8" standalone="no"?>
<billStatus>
  <version>3.0.0</version>
  <bill>
    <number>1551</number>
    <updateDate>2023-01-13T04:50:21Z</updateDate>
    <updateDateIncludingText>2023-01-13T04:50:21Z</updateDateIncludingText>
    <originChamber>Senate</originChamber>
    <originChamberCode>S</originChamberCode>
    <type>S</type>
    <introducedDate>2005-07-28</introducedDate>
    <congress>109</congress>
    <committees>
      <item>
        <systemCode>ssfi00</systemCode>
        <name>Finance Committee</name>
        <chamber>Senate</chamber>
        <type>Standing</type>
        <activities>
          <item>
            <name>Referred to</name>
            <date>2005-07-29T00:38:09Z</date>
          </item>
        </activities>
      </item>
    </committees>
    <relatedBills>
      <item>
        <title>Protecting Free Trade in Pharmaceuticals Act of 2005</title>
        <congress>109</congress>
        <number>3583</number>
        <type>HR</type>
        <latestAction>
          <actionDate>2005-08-04</actionDate>
          <text>Referred to the Subcommittee on Trade.</text>
        </latestAction>
        <relationshipDetails>
          <item>
            <type>Identical bill</type>
            <identifiedBy>CRS</identifiedBy>
          </item>
        </relationshipDetails>
      </item>
    </relatedBills>
    <actions>
      <item>
        <actionDate>2005-07-28</actionDate>
        <committees>
          <item>
            <systemCode>ssfi00</systemCode>
            <name>Finance Committee</name>
          </item>
        </committees>
        <sourceSystem>
          <name>Senate</name>
        </sourceSystem>
        <text>Read twice and referred to the Committee on Finance.</text>
        <type>IntroReferral</type>
      </item>
      <item>
        <actionDate>2005-07-28</actionDate>
        <text>Introduced in Senate</text>
        <type>IntroReferral</type>
        <actionCode>10000</actionCode>
        <sourceSystem>
          <code>9</code>
          <name>Library of Congress</name>
        </sourceSystem>
      </item>
    </actions>
    <sponsors>
      <item>
        <bioguideId>V000127</bioguideId>
        <fullName>Sen. Vitter, David [R-LA]</fullName>
        <firstName>David</firstName>
        <lastName>Vitter</lastName>
        <party>R</party>
        <state>LA</state>
        <isByRequest>N</isByRequest>
      </item>
    </sponsors>
    <cosponsors>
      <item>
        <bioguideId>S000770</bioguideId>
        <fullName>Sen. Stabenow, Debbie [D-MI]</fullName>
        <firstName>Debbie</firstName>
        <lastName>Stabenow</lastName>
        <party>D</party>
        <state>MI</state>
        <sponsorshipDate>2005-07-28</sponsorshipDate>
        <isOriginalCosponsor>True</isOriginalCosponsor>
      </item>
      <item>
        <bioguideId>M000303</bioguideId>
        <fullName>Sen. McCain, John [R-AZ]</fullName>
        <firstName>JOHN</firstName>
        <lastName>MCCAIN</lastName>
        <party>R</party>
        <state>AZ</state>
        <middleName>SIDNEY</middleName>
        <sponsorshipDate>2005-07-28</sponsorshipDate>
        <isOriginalCosponsor>True</isOriginalCosponsor>
      </item>
    </cosponsors>
    <policyArea>
      <name>Foreign Trade and International Finance</name>
    </policyArea>
    <subjects>
      <legislativeSubjects>
        <item>
          <name>Commerce</name>
        </item>
        <item>
          <name>Congress</name>
        </item>
        <item>
          <name>Consumer protection</name>
        </item>
        <item>
          <name>Drugs</name>
        </item>
        <item>
          <name>Federal advisory bodies</name>
        </item>
        <item>
          <name>Government Operations and Politics</name>
        </item>
        <item>
          <name>Health</name>
        </item>
        <item>
          <name>Imports</name>
        </item>
        <item>
          <name>Intellectual property</name>
        </item>
        <item>
          <name>International Affairs</name>
        </item>
        <item>
          <name>Legislation</name>
        </item>
        <item>
          <name>Patent infringement</name>
        </item>
        <item>
          <name>Patents</name>
        </item>
        <item>
          <name>Trade agreements</name>
        </item>
        <item>
          <name>Trade negotiations</name>
        </item>
      </legislativeSubjects>
      <policyArea>
        <name>Foreign Trade and International Finance</name>
      </policyArea>
    </subjects>
    <summaries>
      <summary>
        <versionCode>00</versionCode>
        <actionDate>2005-07-28</actionDate>
        <actionDesc>Introduced in Senate</actionDesc>
        <updateDate>2005-09-06T21:24:24Z</updateDate>
        <text><![CDATA[ <p>Protecting Free Trade in Pharmaceuticals Act of 2005 - Amends the Bipartisan Trade Promotion Authority Act of 2002 to include among the overall trade negotiating objectives of the United States avoiding negotiating trade agreements that could restrict, or be interpreted to restrict, the access of consumers in the United States to pharmaceutical imports from countries with a pharmaceutical infrastructure that is equivalent, or superior, to that of the United States: (1) by or through the use and development of the doctrine of international patent exhaustion, as interpreted or applied by U.S. courts on the enactment of this Act; or (2) by making it a violation for the United States to enact legislation permitting pharmaceutical imports without the consent of patent owners when the products involved have been sold outside the United States.</p> <p>Prohibits the U.S. Trade Representative (USTR) from: (1) entering into a bilateral or multilateral trade agreement that, with respect to the importation of pharmaceutical products without the consent of the patent owners, includes provisions identical or similar to the provisions of the United States-Singapore Free Trade Agreement, the United States-Australia Free Trade Agreement, or the United States-Morocco Free Trade Agreement; or (2) negotiating an agreement or understanding with respect to any of such provisions.</p> <p>Requires the USTR, with respect to the advisory committee on matters relating to intellectual property, to ensure that, for each meeting that relates or potentially relates to the importation of pharmaceutical products into the United States, at least 10% of the committee members represent the interests of consumers of such products.</p>]]></text>
      </summary>
    </summaries>
    <title>Protecting Free Trade in Pharmaceuticals Act of 2005</title>
    <titles>
      <item>
        <titleType>Display Title</titleType>
        <title>Protecting Free Trade in Pharmaceuticals Act of 2005</title>
      </item>
      <item>
        <titleType>Official Title as Introduced</titleType>
        <title>A bill to clarify that the overall trade negotiating objectives of the United States include avoiding provisions in trade agreements that restrict the access of consumers in the United States to pharmaceutical imports, and for other purposes.</title>
        <billTextVersionName>Introduced in Senate</billTextVersionName>
        <billTextVersionCode>IS</billTextVersionCode>
      </item>
      <item>
        <titleType>Short Titles as Introduced</titleType>
        <title>Protecting Free Trade in Pharmaceuticals Act of 2005</title>
      </item>
    </titles>
    <textVersions>
      <item>
        <type>Introduced in Senate</type>
        <date>2005-07-28T04:00:00Z</date>
        <formats>
          <item>
            <url>https://www.govinfo.gov/content/pkg/BILLS-109s1551is/xml/BILLS-109s1551is.xml</url>
          </item>
        </formats>
      </item>
    </textVersions>
    <latestAction>
      <actionDate>2005-07-28</actionDate>
      <text>Read twice and referred to the Committee on Finance.</text>
    </latestAction>
  </bill>
  <dublinCore xmlns:dc="http://purl.org/dc/elements/1.1/">
    <dc:format>text/xml</dc:format>
    <dc:language>EN</dc:language>
    <dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
    <dc:contributor>Congressional Research Service, Library of Congress</dc:contributor>
    <dc:description>This file contains bill summaries and statuses for federal legislation. A bill summary describes the most significant provisions of a piece of legislation and details the effects the legislative text may have on current law and federal programs. Bill summaries are authored by the Congressional Research Service (CRS) of the Library of Congress. As stated in Public Law 91-510 (2 USC 166 (d)(6)), one of the duties of CRS is "to prepare summaries and digests of bills and resolutions of a public general nature introduced in the Senate or House of Representatives". For more information, refer to the User Guide that accompanies this file.</dc:description>
  </dublinCore>
</billStatus>
